



Coming Soon

MSMilan 2023 Real-World Utilization of a  
Proteomic Biomarker Panel for Assessing  
Multiple Sclerosis Disease Activity in an  
Academic Multiple Sclerosis Clinic with a  
Diverse Patient Population P232